The trial will investigate whether two chemotherapies can clear out a tumor in mice before allowing for human participants, and Science reported this measure is “unusually rigorous.”
Because of the scale of the study — which will include at least 2,000 patients — the National Cancer Institute said it will search for cancer patients with unique mutations. It will also research multiple combinations of drugs, both approved and investigational ones contributed by drugmakers.
“Hundreds of thousands of potential drug combinations exist, so one challenge has been to narrow down and prioritize the most promising ones,” the institute said in a news release.
The project will start with 12 small trials of advanced cancer patients who have not seen success with standard therapies.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
